Virologic responses to pegylated-interferon α-2a plus ribavirin therapy for cryoglobulinemia positive chronic hepatitis C in patients with hepatitis C virus genotype 1b
10.3760/cma.j.issn.1674-2397.2014.02.012
- VernacularTitle:聚乙二醇干扰素α-2a联合利巴韦林治疗冷球蛋白血症阳性的基因1b型慢性丙型肝炎病毒学应答分析
- Author:
Chun ZHANG
;
Weihong WANG
- Publication Type:Journal Article
- Keywords:
Hepatitis C,chronic;
Cryoglobulinemia;
Interferon α;
Ribavirin
- From:
Chinese Journal of Clinical Infectious Diseases
2014;7(2):157-160
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the virologic responses to pegylated-interferon alfa-2a (PegIFNα-2a) plus ribavirin therapy for cryoglobulinemia positive chronic hepatitis C in patients with hepatitis C virus (HCV) genotype 1 b.Methods Clinical data on 60 chronic hepatitis C patients with HCV genotype 1b were collected from Huzhou Central Hospital during January 2008 and December 2012.The patients were divided into cryoglobulinemia positive group (n =22) and cryoglobulinemia negative group (n =38),and both received 48-week PegIFNα-2a (180 μg) plus ribavirin treatments.For those who could not tolerate the treatment,PeglFNα-2a was reduced to 135 μg from 12th week.Rapid virologic response (RVR),end of treatment virologic response (ETVR) and sustained virologic response (SVR) in two groups were observed and compared using Chi-square test.Results RVR,ETVR and SVR in cryoglobulinemia positive group were 59.1％ (13/22),81.8％ (18/22) and 31.8％ (7/22),while those in cryoglobulinemia negative group were 55.3％ (21/38),76.3％ (29/38) and 60.5％ (23/38).There was significant difference in SVRs between two groups (x2 =4.674,P ＜ 0.05).For those completed full course of antiviral therapy with 180 μg PegIFNα-2a,the RVR and SVR in cryoglobulinemia negative group tended to be higher than those in cryoglobulinemia positive group,but the differences were not statistically significant (x2 =1.524 and 1.009,P ＞ 0.05).Serious adverse reactions were observed in 9 (40.9％) patients of cryoglobulinemia positive group,while in 11 (28.9％) patients of cryoglobulinemia negative group (x2 =0.887,P ＞ 0.05).Conclusion Cryoglobulinemia may not have considerable impact on virologic responses to PegIFNα-2a plus ribavirin therapy in patients with chronic genotype 1b hepatitis C.
